Why Anacor Is Poised to Pull Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Anacor Pharmaceuticals (NASDAQ: ANAC  ) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Anacor and see what CAPS investors are saying about the stock right now.

Anacor facts

Headquarters (founded)

Palo Alto, Calif. (2000)

Market Cap

$224.6 million

Industry

Biotechnology

Trailing-12-Month Revenue

$10.7 million

Management

CEO David Perry
CFO Geoffrey Parker

Return on Capital (average, past 3 years)

(62.1%)

Cash/Debt

$45.5 million / $25.7 million

Competitors

Johnson & Johnson
Novartis
Sanofi

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 40% of the 43 members who have rated Anacor believe the stock will underperform the S&P 500 going forward.

Earlier this morning, one of those Fools, All-Star zzlangerhans, succinctly summed up the Anacor bear case for our community:

As predicted, in March the stock rebounded from the weak phase III performance of tavaborole with positive results from dose-ranging phase II trial of AN2728 in atopic dermatitis. But [$220M] is simply too much for a phase II drug in the crowded indication of atopic dermatitis. Anacor will certainly raise big before getting close to topline data from a phase III trial of AN2728, and approval of Valeant's efinaconazole in May will provide another nail for tavaborole's coffin.

While you can certainly make huge gains in biotechs, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 08, 2013, at 7:35 PM, tonymagoo wrote:

    It looks like some of our star fools were incorrect on ANACOR. The Gates Foundation's grant and investment sure looks to be the booster charge that ANACOR needs until some Phase III additional data comes in for its high margin products. Until then, research will continue and may they find some additional wonderful treatments for the disease laden parts of our world.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2343847, ~/Articles/ArticleHandler.aspx, 9/15/2014 12:31:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement